AbbVie Inc. (ABBV)
3 Top AI-Powered Biotech Stocks to Buy in February
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Buy, Sell, Or Hold ABBV Stock At $185?
AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectively.
2 Undervalued Dividend Stocks Ready For A Major Comeback
The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong recovery potential. The other is a high-yield healthcare gem with anti-cyclical resilience. Both stocks offer market-beating potential, solid dividends, and long-term growth. They're perfect for balancing risk and reward in today's uncertain economy.
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start.
AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance for 2025 and beyond is bullish, projecting high single-digit revenue growth through 2029, with Skyrizi and Rinvoq expected to generate $31 billion in combined sales by 2027. AbbVie's M&A strategy faced setbacks, notably with the Cerevel acquisition, but the company remains optimistic about future approvals and growth in oncology and neuroscience.
AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion in revenue and $12.12-$12.32 adjusted EPS, and includes a worse outlook for Humira and additional headwinds from the Medicare Part D benefit redesign. Management expects high single-digit revenue growth through 2029, and over the next eight years, as there are no major products losing exclusivity throughout this period.
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs
ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
Why AbbVie Stock Is Jumping Today
Shares of AbbVie (ABBV 6.98%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day.
AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV ) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Rob Michael - Chief Executive Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Carrie Strom - Senior Vice President of AbbVie, and President of Global Allergan Aesthetics Conference Call Participants Vamil Divan - Guggenheim Securities Chris Schott - J.P. Morgan Geoff Meacham - Citigroup Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Tim Anderson - Bank of America Chris Raymond - Piper Sandler Trung Huynh - UBS Chris Shibutani - Goldman Sachs Operator Good morning and thank you for standing by.
